A$5.0 million commitment received from Australian-based private investor A$10.8 million Entitlement Offer at the same offer price as the placement Funds to support Phase III Topical clinical trials in ...
Independent Safety Committee unanimously agrees that the Phase I/II trial is safe, well tolerated, and fit for expanded access Study achieving primary endpoints of safety, tolerability, and efficacy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results